

Payments from drug companies to physicians are associated with expensive opioid analgesic prescribing

PLoS ONE

13, e0209383

DOI: [10.1371/journal.pone.0209383](https://doi.org/10.1371/journal.pone.0209383)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Open data on industry payments to healthcare providers reveal potential hidden costs to the public. Nature Communications, 2019, 10, 4314.	5.8	15
2	Competence and confidence with prescribing in pharmacy and medicine: a scoping review. International Journal of Pharmacy Practice, 2020, 28, 312-325.	0.3	23
3	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence-Based Medicine, 2022, 27, 46-54.	1.7	16
4	Association between industry payments for opioid products and physicians' prescription of opioids: observational study with propensity-score matching. Journal of Epidemiology and Community Health, 2020, 74, jech-2020-214021.	2.0	13
5	What proportion of patients with chronic noncancer pain are prescribed an opioid medicine? Systematic review and meta-analysis of observational studies. Journal of Internal Medicine, 2020, 287, 458-474.	2.7	42
6	Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?. Annals of Internal Medicine, 2021, 174, 353-361.	2.0	124
7	Patient factors associated with oral generic olanzapine initiation and substitution among Medicaid beneficiaries: a new user cohort study. Current Medical Research and Opinion, 2021, 37, 655-664.	0.9	1
8	A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough. Journal of General Internal Medicine, 2021, 36, 3194-3198.	1.3	25
9	Industry Payments to Pain Medicine Physicians: An Analysis of the Centers for Medicare and Medicaid Services Open Payments Program. Pain Medicine, 2021, 22, 1376-1386.	0.9	2
10	Industry payments and physicians prescriptions: Effect of a payment restriction policy. Social Science and Medicine, 2021, 278, 113942.	1.8	4
11	Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review. British Journal of Cancer, 2022, 126, 144-161.	2.9	5
12	Effects and Trends in Opioid-Related Promotional Payments Between 2014 and 2019: a Panel Data Analysis Among Prescribers in Medicare Part D. Journal of General Internal Medicine, 2022, , 1.	1.3	1
13	Pharmaceutical Company Payments to Healthcare Professionals and Healthcare Organizations in Canada: An Observational Study. Healthcare Policy, 2022, 17, 42-48.	0.3	1
14	Bias amplification in the g-computation algorithm for time-varying treatments: a case study of industry payments and prescription of opioid products. BMC Medical Research Methodology, 2022, 22, 120.	1.4	0
15	Pharmaceuticals as a Specific Consumer Goods. Factors Affecting the Increase in Drug Consumption – The Sociological Perspective. Konteksty Społeczne, 2021, 8, 206-233.	0.0	1
16	Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?. Journal of Health Politics, Policy and Law, 2022, 47, 815-833.	0.9	4
17	Association Between Open Payments' Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US. JAMA Ophthalmology, 2022, 140, 855.	1.4	5
18	The Role of Physician Networks and Receipt of Opioid-Related Payments. Journal of General Internal Medicine, 0, , .	1.3	1

#	ARTICLE	IF	CITATIONS
19	The Trend in Industry Payments During the COVID-19 Pandemic Among Gastroenterologists and Hepatologists in the United States. Cureus, 2022, , .	0.2	0
20	Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief. Frontiers in Public Health, 0, 10, .	1.3	1